GYRE Gyre Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GYRE

Price (delayed)

$23.52

Market cap

$59.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$20.7

Enterprise value

$57.32M

catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic ...

Highlights
Gyre Therapeutics's debt has shrunk by 100% YoY
GYRE's gross profit has surged by 100% year-on-year
The company's equity has surged by 112% QoQ but it has shrunk by 88% YoY
GYRE's quick ratio has dropped by 73% year-on-year but it is up by 10% since the previous quarter
GYRE's revenue has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology

Key stats

What are the main financial stats of GYRE
Market
Shares outstanding
2.53M
Market cap
$59.55M
Enterprise value
$57.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
16.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.88M
EBITDA
-$43.86M
Free cash flow
-$13.33M
Per share
EPS
-$20.7
Free cash flow per share
-$5.26
Book value per share
$1.39
Revenue per share
$0
TBVPS
$3.94
Balance sheet
Total assets
$9.96M
Total liabilities
$6.45M
Debt
$0
Equity
$3.52M
Working capital
$3.35M
Liquidity
Debt to equity
0
Current ratio
2.88
Quick ratio
4.54
Net debt/EBITDA
0.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-254.4%
Return on equity
N/A
Return on invested capital
-7,222.7%
Return on capital employed
-536.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GYRE stock price

How has the Gyre Therapeutics stock price performed over time
Intraday
-10.57%
1 week
46%
1 month
206.67%
1 year
181.21%
YTD
197.25%
QTD
225.11%

Financial performance

How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.26M
Net income
-$44.24M
Gross margin
N/A
Net margin
N/A
GYRE's revenue has dropped by 100% year-on-year
GYRE's gross profit has surged by 100% year-on-year
The net income has grown by 7% from the previous quarter
GYRE's operating income is up by 7% since the previous quarter

Growth

What is Gyre Therapeutics's growth rate over time

Valuation

What is Gyre Therapeutics stock price valuation
P/E
N/A
P/B
16.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GYRE's EPS is up by 8% since the previous quarter
The company's equity has surged by 112% QoQ but it has shrunk by 88% YoY
GYRE's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Gyre Therapeutics business performance
Gyre Therapeutics's ROA has decreased by 21% from the previous quarter
GYRE's ROIC is down by 20% from the previous quarter

Dividends

What is GYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GYRE.

Financial health

How did Gyre Therapeutics financials performed over time
GYRE's total assets is 55% greater than its total liabilities
GYRE's current ratio has dropped by 84% year-on-year but it is up by 5% since the previous quarter
GYRE's quick ratio has dropped by 73% year-on-year but it is up by 10% since the previous quarter
Gyre Therapeutics's debt is 100% lower than its equity
The company's equity has surged by 112% QoQ but it has shrunk by 88% YoY
Gyre Therapeutics's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.